Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-17, Stock:LLY, The news for the past five days is as follows:
2019-10-10: NEWS1: Here’s What Hedge Funds Think About Eli Lilly and Company (LLY).NEWS2: 3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates.NEWS3: J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector.NEWS4: Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study.
2019-10-11: NEWS1: Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval.NEWS2: UPDATE 1-Eli Lilly's migraine treatment wins U.S. FDA approval.NEWS3: Eli Lilly's migraine treatment wins U.S. FDA approval.NEWS4: Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals.NEWS5: Gilead-Galapagos Report Efficacy & Safety Results on RA Drug.NEWS6: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout.
2019-10-14: NEWS1: 52-Week Company Lows.NEWS2: Lilly Gets FDA Approval for New Oral Tablets for Migraine.NEWS3: Eli Lilly Stock Gets 2 Pieces of Good News.
2019-10-15: NEWS1: Health savings accounts provide benefits, tax advantages.NEWS2: This is Why Eli Lilly (LLY) is a Great Dividend Stock.
2019-10-16: NEWS1: Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth.NEWS2: U.S. Stocks Set to Fall on Renewed China Concerns.NEWS3: Lilly's pancreatic cancer treatment fails late-stage study.NEWS4: Eli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival.NEWS5: Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival.NEWS6: How to Cut Your 2019 Tax Bill Before It’s Too Late.NEWS7: Eli Lilly Phase 3 Pancreatic Cancer Study Fails to Meet Primary Endpoint.

Answer: Rise